Targeting key proximal drivers of type 2 inflammation in disease
The DOI matches its Crossref record; 154 of the 156 references it cites were found in a registry or an index.
Abstract
Systemic type 2 inflammation encompassing T helper 2 (TH2)-type responses is emerging as a unifying feature of both classically defined allergic diseases, such as asthma, and a range of other inflammatory diseases. Rather than reducing inflammation with broad-acting immunosuppressants or narrowly targeting downstream products of the TH2 pathway, such as immunoglobulin E (IgE), efforts to target the key proximal type 2 cytokines - interleukin-4 (IL-4), IL-5 and IL-13 - represent a promising strategy to achieve therapeutic benefit across multiple diseases. After several initial disappointing clinical results with therapies targeting IL-4, IL-5 or IL-13 in asthma, applying a personalized approach achieved therapeutic benefit in an asthma subtype exhibiting an 'allergic' phenotype. More recently, efficacy was extended into a broad population of people with asthma. This argues that the Type 2 inflammation is broadly relevant across the severe asthma population if the key upstream drivers are properly blocked. Moreover, the simultaneous inhibition of IL-4 and IL-13 has shown significant clinical activity in diseases that are often co-morbid with asthma - atopic dermatitis and chronic sinusitis with nasal polyps - supporting the hypothesis that targeting a central 'driver pathway' could benefit multiple allergic diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lebrikizumab does not affect the binding of IL-13 to the IL-13Rα2 receptor chain, the biological role of which remains unclear81.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [81]
Citations
Cites
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
Asher, M. I., Montefort, S., Björkstén, B., Lai, C. K., Strachan, D. P., Weiland, S. K., & Williams, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69283-0 · Cited by 4,223
Interleukin-13: Central Mediator of Allergic Asthma
Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L., & Donaldson, D. D. (1998) · Science · doi:10.1126/science.282.5397.2258 · Cited by 2,617
Development and validation of a questionnaire to measure asthma control
Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473
Fokkens, W. J., Lund, V. J., Mullol, J., Bachert, C., Alobid, I., Baroody, F., Cohen, N., Cervin, A., Douglas, R., Gevaert, P., et al. (2012) · Rhinology journal · doi:10.4193/rhino12.000 · Cited by 2,387
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Moore, W. C., Meyers, D. A., Wenzel, S. E., Teague, W. G., Li, H., Li, X., D'Agostino, R., Castro, M., Curran-Everett, D., Fitzpatrick, A. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0896oc · Cited by 2,129
Cluster analysis and clinical asthma phenotypes
Haldar, P., Pavord, I. D., Shaw, D. E., Berry, M. A., Thomas, M., Brightling, C. E., Wardlaw, A. J., & Green, R. H. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1754oc · Cited by 1,987
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,871
Requirement for IL-13 Independently of IL-4 in Experimental Asthma
Grünig, G., Warnock, M., Wakil, A. E., Venkayya, R., Brombacher, F., Rennick, D. M., Sheppard, D., Mohrs, M., Donaldson, D. D., Locksley, R. M., et al. (1998) · Science · doi:10.1126/science.282.5397.2261 · Cited by 1,849
Leckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
Woodruff, P. G., Modrek, B., Choy, D. F., Jia, G., Abbas, A. R., Ellwanger, A., Arron, J. R., Koth, L. L., & Fahy, J. V. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0392oc · Cited by 1,803
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial
Green, R. H., Brightling, C. E., McKenna, S., Hargadon, B., Parker, D., Bradding, P., Wardlaw, A. J., & Pavord, I. D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11679-5 · Cited by 1,755
Zhu, Z., Homer, R. J., Wang, Z., Chen, Q., Geba, G. P., Wang, J., Zhang, Y., & Elias, J. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5909 · Cited by 1,719
Treatment of Childhood Atopic Dermatitis and Economic Burden of Illness in Asia Pacific Countries
Lee, B. W., & Detzel, P. R. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000370221 · Cited by 1,668
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationFoster, P. S., Hogan, S. P., Ramsay, A. J., Matthaei, K. I., & Young, I. G. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.195 · Cited by 1,370
Kay, A. B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101043440106 · Cited by 1,368
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Nair, P., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O'Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,356
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Self-citationBusse, W., Corren, J., Lanier, B. Q., McAlary, M., Fowler-Taylor, A., Cioppa, G. D., van As, A., & Gupta, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.117880 · Cited by 1,307
IL‐4 directs the development of Th2‐like helper effectors
Swain, S. L., Weinberg, A. D., English, M., & Huston, G. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.11.3796 · Cited by 1,254
Disruption of the murine IL-4 gene blocks Th2 cytokine responses
Kopf, M., Gros, G. L., Bachmann, M., Lamers, M. C., Bluethmann, H., & Köhler, G. (1993) · Nature · doi:10.1038/362245a0 · Cited by 1,203
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Leung, D. Y., & Bieber, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12193-9 · Cited by 1,147
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Maurer, M., Rosén, K., Hsieh, H.-J., Saini, S., Grattan, C., Gimenéz-Arnau, A., Agarwal, S., Doyle, R., Canvin, J., Kaplan, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215372 · Cited by 1,105
Asthma: defining of the persistent adult phenotypes
Wenzel, S. E. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69290-8 · Cited by 1,043
Juniper, E. F., Bousquet, J., Abetz, L., & Bateman, E. D. (2006) · Respiratory Medicine · doi:10.1016/j.rmed.2005.08.012 · Cited by 998
Gittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Juniper, E. F., Svensson, K., Mörk, A.-C., & Ståhl, E. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.10.008 · Cited by 929
Rhinosinusitis: Establishing definitions for clinical research and patient care
Meltzer, E. O., Hamilos, D. L., Hadley, J. A., Lanza, D. C., Marple, B. F., Nicklas, R. A., Bachert, C., Baraniuk, J., Baroody, F. M., Benninger, M. S., et al. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.09.029 · Cited by 854
Solèr, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., Thirlwell, J., Gupta, N., & Della Cioppa, G. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00092101 · Cited by 827
Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis.
Hamid, Q., Boguniewicz, M., & Leung, D. Y. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117408 · Cited by 778
Differentiation of chronic sinus diseases by measurement of inflammatory mediators
Van Zele, T., Claeys, S., Gevaert, P., Van Maele, G., Holtappels, G., Van Cauwenberge, P., & Bachert, C. (2006) · Allergy · doi:10.1111/j.1398-9995.2006.01225.x · Cited by 774
A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma
Flood-Page, P., Swenson, C., Faiferman, I., Matthews, J., Williams, M., Brannick, L., Robinson, D., Wenzel, S., Busse, W., Hansel, T. T., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-085oc · Cited by 750
Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma
Gevaert, P., Calus, L., Van Zele, T., Blomme, K., De Ruyck, N., Bauters, W., Hellings, P., Brusselle, G., De Bacquer, D., van Cauwenberge, P., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.047 · Cited by 744
Van Dyken, S. J., & Locksley, R. M. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095906 · Cited by 714
Fahy, J. V., Fleming, H. E., Wong, H. H., Liu, J. T., Su, J. Q., Reimann, J., Fick, R. B., & Boushey, H. A. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.6.9196082 · Cited by 713
Type 2 cytokines: mechanisms and therapeutic strategies
Wynn, T. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3831 · Cited by 678
Takayama, G., Arima, K., Kanaji, T., Toda, S., Tanaka, H., Shoji, S., McKenzie, A. N. J., Nagai, H., Hotokebuchi, T., & Izuhara, K. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.02.046 · Cited by 674
Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis
Gevaert, P., Van Bruaene, N., Cattaert, T., Van Steen, K., Van Zele, T., Acke, F., De Ruyck, N., Blomme, K., Sousa, A. R., Marshall, R. P., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.07.056 · Cited by 629
IL-13 receptors and signaling pathways: An evolving web
Hershey, G. K. K. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.1333 · Cited by 610
A global survey of changing patterns of food allergy burden in children
Prescott, S. L., Pawankar, R., Allen, K. J., Campbell, D. E., Sinn, J. K., Fiocchi, A., Ebisawa, M., Sampson, H. A., Beyer, K., & Lee, B.-W. (2013) · World Allergy Organization Journal · doi:10.1186/1939-4551-6-21 · Cited by 604
Wenzel, S., Wilbraham, D., Fuller, R., Getz, E. B., & Longphre, M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61600-6 · Cited by 588
Kakinuma, T., Nakamura, K., Wakugawa, M., Mitsui, H., Tada, Y., Saeki, H., Torii, H., Asahina, A., Onai, N., Matsushima, K., et al. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.113237 · Cited by 575
Phan, N., Blome, C., Fritz, F., Gerss, J., Reich, A., Ebata, T., Augustin, M., Szepietowski, J., & Ständer, S. (2012) · Acta Dermato Venereologica · doi:10.2340/00015555-1246 · Cited by 575
Imai, T., Baba, M., Nishimura, M., Kakizaki, M., Takagi, S., & Yoshie, O. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.23.15036 · Cited by 555
Molecular and Structural Basis of Cytokine Receptor Pleiotropy in the Interleukin-4/13 System
LaPorte, S. L., Juo, Z. S., Vaclavikova, J., Colf, L. A., Qi, X., Heller, N. M., Keegan, A. D., & Garcia, K. C. (2008) · Cell · doi:10.1016/j.cell.2007.12.030 · Cited by 517
Suárez-Fariñas, M., Dhingra, N., Gittler, J., Shemer, A., Cardinale, I., de Guzman Strong, C., Krueger, J. G., & Guttman-Yassky, E. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.04.046 · Cited by 483
Saini, S. S., Bindslev-Jensen, C., Maurer, M., Grob, J.-J., Bülbül Baskan, E., Bradley, M. S., Canvin, J., Rahmaoui, A., Georgiou, P., Alpan, O., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.306 · Cited by 471
Hamilton, J. D., Suárez-Fariñas, M., Dhingra, N., Cardinale, I., Li, X., Kostic, A., Ming, J. E., Radin, A. R., Krueger, J. G., Graham, N., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.013 · Cited by 469
Self-citationSuárez-Fariñas, M., Tintle, S. J., Shemer, A., Chiricozzi, A., Nograles, K., Cardinale, I., Duan, S., Bowcock, A. M., Krueger, J. G., & Guttman-Yassky, E. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.12.1124 · Cited by 464
Kurowska-Stolarska, M., Kewin, P., Murphy, G., Russo, R. C., Stolarski, B., Garcia, C. C., Komai-Koma, M., Pitman, N., Li, Y., McKenzie, A. N. J., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4780 · Cited by 460
Kam, J. C., Szefler, S. J., Surs, W., Sher, E. R., & Leung, D. Y. M. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.7.3460 · Cited by 449
Nasal IL-5 levels determine the response to anti–IL-5 treatment in patients with nasal polyps
Gevaert, P., Lang-Loidolt, D., Lackner, A., Stammberger, H., Staudinger, H., Van Zele, T., Holtappels, G., Tavernier, J., van Cauwenberge, P., & Bachert, C. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.05.031 · Cited by 442
Attenuation of allergic airway inflammation in IL‐4 deficient mice
BRUSSELLE, G. G., KIPS, J. C., TAVERNIER, J. H., VAN DER HEYDEN, J. G., CUVELIER, C. A., PAUWELS, R. A., & BLUETHMANN, H. (1994) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.1994.tb00920.x · Cited by 431
Eosinophil trafficking in allergy and asthma
Rosenberg, H. F., Phipps, S., & Foster, P. S. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.03.048 · Cited by 428
IL-5- and eosinophil-mediated inflammation: from discovery to therapy
Kouro, T., & Takatsu, K. (2009) · International Immunology · doi:10.1093/intimm/dxp102 · Cited by 422
Interleukin-4 Receptor in Moderate Atopic Asthma: A Phase I/II Randomized, Placebo-controlled Trial
BORISH, L. C., NELSON, H. S., LANZ, M. J., CLAUSSEN, L., WHITMORE, J. B., AGOSTI, J. M., & GARRISON, L. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.6.9808146 · Cited by 418
Association of Glucocorticoid Insensitivity with Increased Expression of Glucocorticoid Receptor β
Leung, D. Y. M., Hamid, Q., Vottero, A., Szefler, S. J., Surs, W., Minshall, E., Chrousos, G. P., & Klemm, D. J. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.9.1567 · Cited by 415
Efficacy of soluble IL-4 receptor for the treatment of adults with asthma
Borish, L. C., Nelson, H. S., Corren, J., Bensch, G., Busse, W. W., Whitmore, J. B., & Agosti, J. M. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.115624 · Cited by 411
Mechanisms of airway hyperresponsiveness
COCKCROFT, D., & DAVIS, B. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.07.012 · Cited by 411
Bentley, A. M., Menz, G., Storz, C., Robinson, D. S., Bradley, B., Jeffery, P. K., Durham, S. R., & Kay, A. B. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/146.2.500 · Cited by 407
Ying, S., Humbert, M., Barkans, J., Corrigan, C. J., Pfister, R., Menz, G., Larché, M., Robinson, D. S., Durham, S. R., & Kay, A. B. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.7.3539 · Cited by 407
Oral steroids and doxycycline: Two different approaches to treat nasal polyps
Van Zele, T., Gevaert, P., Holtappels, G., Beule, A., Wormald, P. J., Mayr, S., Hens, G., Hellings, P., Ebbens, F. A., Fokkens, W., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.02.020 · Cited by 402
Critical Role for IL-13 in the Development of Allergen-Induced Airway Hyperreactivity
Walter, D. M., McIntire, J. J., Berry, G., McKenzie, A. N. J., Donaldson, D. D., DeKruyff, R. H., & Umetsu, D. T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4668 · Cited by 396
Eosinophilic and Neutrophilic Inflammation in Asthma: Insights from Clinical Studies
Fahy, J. V. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200808-087rm · Cited by 389
Impaired Development of Th2 Cells in IL-13-Deficient Mice
McKenzie, G. J., Emson, C. L., Bell, S. E., Anderson, S., Fallon, P., Zurawski, G., Murray, R., Grencis, R., & McKenzie, A. N. J. (1998) · Immunity · doi:10.1016/s1074-7613(00)80625-1 · Cited by 381
Cytokine traps: multi-component, high-affinity blockers of cytokine action
Economides, A. N., Carpenter, L. R., Rudge, J. S., Wong, V., Koehler-Stec, E. M., Hartnett, C., Pyles, E. A., Xu, X., Daly, T. J., Young, M. R., et al. (2003) · Nature Medicine · doi:10.1038/nm811 · Cited by 359
Self-citationMcKenzie, G. J., Fallon, P. G., Emson, C. L., Grencis, R. K., & McKenzie, A. N. J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.10.1565 · Cited by 354
Finkelman, F. D., Katona, I. M., Urban, J. F., Snapper, C. M., Ohara, J., & Paul, W. E. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.24.9675 · Cited by 349
Noben-Trauth, N., Shultz, L. D., Brombacher, F., Urban, J. F., Gu, H., & Paul, W. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10838 · Cited by 344
Rankin, J. A., Picarella, D. E., Geba, G. P., Temann, U. A., Prasad, B., DiCosmo, B., Tarallo, A., Stripp, B., Whitsett, J., & Flavell, R. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7821 · Cited by 344
Oldhoff, J. M., Darsow, U., Werfel, T., Katzer, K., Wulf, A., Laifaoui, J., Hijnen, D. J., Plötz, S., Knol, E. F., Kapp, A., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00791.x · Cited by 339
Kay, A. B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101113440206 · Cited by 321
Integrated Signals Between IL-13, IL-4, and IL-5 Regulate Airways Hyperreactivity
Webb, D. C., McKenzie, A. N. J., Koskinen, A. M. L., Yang, M., Mattes, J., & Foster, P. S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.1.108 · Cited by 311
Chan, L. S., Robinson, N., & Xu, L. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01484.x · Cited by 306
A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4Rα Antagonist, in Patients with Asthma
Corren, J., Busse, W., Meltzer, E. O., Mansfield, L., Bensch, G., Fahrenholz, J., Wenzel, S. E., Chon, Y., Dunn, M., Weng, H. H., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200909-1448oc · Cited by 299
Mochizuki, M., Bartels, J., Mallet, A. I., Christophers, E., & Schröder, J.-M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.1.60 · Cited by 291
Grewe, M., Walther, S., Gyufko, K., Czech, W., Schöpf, E., & Krutmann, J. (1995) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12321078 · Cited by 289
Bentley, A. M. (1992) · Medical Entomology and Zoology · Cited by 282
Hijnen, D., de Bruin-Weller, M., Oosting, B., Lebre, C., de Jong, E., Bruijnzeel-Koomen, C., & Knol, E. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.12.007 · Cited by 269
Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma
Oh, C. K., Geba, G. P., & Molfino, N. (2010) · European Respiratory Review · doi:10.1183/09059180.00007609 · Cited by 256
Mohrs, M., Ledermann, B., Köhler, G., Dorfmüller, A., Gessner, A., & Brombacher, F. (1999) · PubMed · Cited by 243
A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis
Pinto, J. M., Mehta, N., DiTineo, M., Wang, J., Baroody, F. M., & Naclerio, R. M. (2010) · Rhinology Journal · doi:10.4193/rhin09.144 · Cited by 238
Effects of Interleukin-13 Blockade on Allergen-induced Airway Responses in Mild Atopic Asthma
Gauvreau, G. M., Boulet, L.-P., Cockcroft, D. W., FitzGerald, J. M., Carlsten, C., Davis, B. E., Deschesnes, F., Duong, M., Durn, B. L., Howie, K. J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201008-1210oc · Cited by 230
CHU, H. W., HALLIDAY, J. L., MARTIN, R. J., LEUNG, D. Y. M., SZEFLER, S. J., & WENZEL, S. E. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.6.9712073 · Cited by 227
Cockcroft, D. W. (2010) · Chest · doi:10.1378/chest.10-0088 · Cited by 222
Mohrs, M., Ledermann, B., Köhler, G., Dorfmüller, A., Gessner, A., & Brombacher, F. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.12.7302 · Cited by 221
Zheng, T., Oh, M. H., Oh, S. Y., Schroeder, J. T., Glick, A. B., & Zhu, Z. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.295 · Cited by 220
LAPORTE, J. C., MOORE, P. E., BARALDO, S., JOUVIN, M.-H., CHURCH, T. L., SCHWARTZMAN, I. N., PANETTIERI, R. A., KINET, J.-P., & SHORE, S. A. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.1.2008060 · Cited by 219
Interleukin-4 receptor signaling pathways in asthma pathogenesis
Chatila, T. A. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.08.004 · Cited by 211
Barner, M., Mohrs, M., Brombacher, F., & Kopf, M. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70256-8 · Cited by 208
Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice
Gavett, S. H., O'Hearn, D. J., Karp, C. L., Patel, E. A., Schofield, B. H., Finkelman, F. D., & Wills-Karp, M. (1997) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1997.272.2.l253 · Cited by 200
Heil, P. M., Maurer, D., Klein, B., Hultsch, T., & Stingl, G. (2010) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2010.07497.x · Cited by 197
Infliximab in the treatment of moderate to severe atopic dermatitis
Jacobi, A., Antoni, C., Manger, B., Schuler, G., & Hertl, M. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.11.022 · Cited by 192
Haeck, I. M., Knol, M. J., ten Berge, O., van Velsen, S. G. A., de Bruin-Weller, M. S., & Bruijnzeel-Koomen, C. A. F. M. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.04.027 · Cited by 177
Noonan, M., Chervinsky, P., Brandon, M., Zhang, J., Kundu, S., McBurney, J., & Reiss, T. (1998) · European Respiratory Journal · doi:10.1183/09031936.98.11061232 · Cited by 175
Structural Basis of Signaling Blockade by Anti-IL-13 Antibody Lebrikizumab
Ultsch, M., Bevers, J., Nakamura, G., Vandlen, R., Kelley, R. F., Wu, L. C., & Eigenbrot, C. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.01.024 · Cited by 174
Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids
Noonan, M., Korenblat, P., Mosesova, S., Scheerens, H., Arron, J. R., Zheng, Y., Putnam, W. S., Parsey, M. V., Bohen, S. P., & Matthews, J. G. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.03.051 · Cited by 171
Jahnz‐Rozyk, K., Targowski, T., Paluchowska, E., Owczarek, W., & Kucharczyk, A. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00774.x · Cited by 168
Barbier, N., Paul, C. F., Luger, T. A., Allen, R., Prost, Y. D., Papp, K. A., Eichenfield, L. F., Cherill, R., & Hanifin, J. M. (2004) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2004.05696.x · Cited by 154
A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis
Pinto, J. M., Mehta, N., DiTineo, M., et al. (2010) · Rhinology Journal · doi:10.4193/rhino09.144 · Cited by 149
STAT6 Mediates Eotaxin-1 Expression in IL-4 or TNF-α-Induced Fibroblasts
Horejs‐Hoeck, J., & Woisetschläger, M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.7.4507 · Cited by 131
Targeting Interleukin-4 in Asthma: Lost in Translation?
Maes, T., Joos, G., & Brusselle, G. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0080tr · Cited by 130
The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge
Scheerens, H., Arron, J. R., Zheng, Y., Putnam, W. S., Erickson, R. W., Choy, D. F., Harris, J. M., Lee, J., Jarjour, N. N., & Matthews, J. G. (2013) · Clinical & Experimental Allergy · doi:10.1111/cea.12220 · Cited by 128
Jeong, C. ‐., Ahn, K., Rho, N., Park, Y., Lee, D. ‐., Lee, J., Lee, E. ‐., & Yang, J. (2003) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2003.01782.x · Cited by 124
Kanoh, S., Tanabe, T., & Rubin, B. K. (2011) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2011.03852.x · Cited by 123
Grunewald, S. M., Werthmann, A., Schnarr, B., Klein, C. E., Bröcker, E., Mohrs, M., Brombacher, F., Sebald, W., & Duschl, A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.8.4004 · Cited by 121
Monoclonal anti-interleukin‐5 treatment suppresses eosinophil but not T‐cell functions
Büttner, C., Lun, A., Splettstoesser, T., Kunkel, G., & Renz, H. E. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00027302 · Cited by 120
Saini, S. S., Bindslev‐Jensen, C., Maurer, M., Grob, J., Başkan, E. B., Bradley, M. S., Canvin, J., Rahmaoui, A., Georgiou, P., Alpan, O., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.512 · Cited by 115
Komai, M., Tanaka, H., Masuda, T., Nagao, K., Ishizaki, M., Sawada, M., & Nagai, H. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705105 · Cited by 107
Cytokine-directed therapies for the treatment of chronic airway diseases
Barnes, P. J. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00058-3 · Cited by 105
A review of treatment with mepolizumab, an anti–IL-5 mAb, in hypereosinophilic syndromes and asthma
Busse, W. W., Ring, J., Huss‐Marp, J., & Kahn, J. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.048 · Cited by 105
LOCALIZATION OF HUMAN INTERLEUKIN 13 RECEPTOR IN NON-HAEMATOPOIETIC CELLS
Akaiwa, M., Yu, B., Suyama, R., Terada, N., Suto, H., Koga, T., Arima, K., Matsushita, S., Saito, H., Ogawa, H., et al. (2001) · Cytokine · doi:10.1006/cyto.2000.0814 · Cited by 103
Molecular interactions between glucocorticoids and long-acting β2-agonists
Adcock, I. M., Maneechotesuwan, K., & Usmani, O. S. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.129705 · Cited by 99
Immunological differences between intrinsic and extrinsic types of atopic dermatitis
Akdiş, C. A., & Akdiş, M. (2003) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2003.01803.x · Cited by 96
Side‐effects of corticosteroid agents
Seale, J. P., & Compton, M. R. (1986) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1986.tb112242.x · Cited by 92
IL‐4 induces expression of TARC/CCL17 via two STAT6 binding sites
Wirnsberger, G., Hebenstreit, D., Posselt, G., Horejs‐Hoeck, J., & Duschl, A. (2006) · European Journal of Immunology · doi:10.1002/eji.200635972 · Cited by 90
Lazarski, C. A., Ford, J. W., Katzman, S. D., Rosenberg, A. F., & Fowell, D. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071949 · Cited by 89
Regulation of murine in vivo lgG and lgE responses by a monoclonal anti-IL-4 receptor antibody
Finkelman, F. D., Urban, J. F., Beckmann, M. P., Schooley, K. A., Holmes, J. M., & Katona, L. M. (1991) · International Immunology · doi:10.1093/intimm/3.6.599 · Cited by 78
Minimizing Complications from Systemic Glucocorticosteroid Use
Nesbitt, L. T. (1995) · Dermatologic Clinics · doi:10.1016/s0733-8635(18)30055-x · Cited by 77
Liddiard, K., Welch, J. S., Lozach, J., Heinz, S., Glass, C. K., & Greaves, D. R. (2006) · BMC Molecular Biology · doi:10.1186/1471-2199-7-45 · Cited by 74
Pathogenesis of chronic rhinosinusitis
Cauwenberge, P. V., Hoecke, H. V., & Bachert, C. (2006) · Current Allergy and Asthma Reports · doi:10.1007/s11882-006-0026-3 · Cited by 71
Pacor, M. L., Lorenzo, G. D., Martinelli, N., Mansueto, P., Rini, G. B., & Corrocher, R. (2004) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2004.1907.x · Cited by 70
Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma
Lee, G. R. (2004) · International Immunology · doi:10.1093/intimm/dxh117 · Cited by 66
Inflammation in Chronic Rhinosinusitis and Nasal Polyposis
van Drunen, C. M., Reinartz, S. M., Wigman, J., & Fokkens, W. J. (2009) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2009.07.003 · Cited by 63
Yamada, T., Sun, Q., Zeibecoglou, K., BUNGRE, J., North, J. M., Kay, A. B., Lopez, A. F., & Robinson, D. S. (1998) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(98)70177-0 · Cited by 59
Oldhoff, J., Darsow, U. G., Werfel, T., Bihari, I. C., Katzer, K., Laifaoui, J., Plötz, S. G., Kapp, A., Knol, E. F., Bruijnzeel-Koomen, C. A. F. M., et al. (2006) · International Archives of Allergy and Immunology · doi:10.1159/000095299 · Cited by 58
Omalizumab for Chronic Urticaria
Maurer, M., Rosén, K. E., & Hsieh, H.-J. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1305687 · Cited by 53
Haeck, I. M., ten Berge, O., van Velsen, S. G. A., de Bruin-Weller, M. S., Bruijnzeel-Koomen, C. A. F. M., & Knol, M. J. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04043.x · Cited by 53
Kakkar, T., Sung, C., Gibiansky, L. V., Vu, T. C., Narayanan, A., Lin, S., Vincent, M. S., Banfield, C. R., Colbert, A., Hoofring, S. A., et al. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0481-y · Cited by 51
Thymic Stromal Lymphopoietin Promotes Lung Inflammation Through Activation of Dendritic Cells
Li, Y., Li, H.-J., Ji, F., Zhang, X., Wang, R., Hao, J.-Q., Bi, W., & Dong, L. (2010) · Journal of Asthma · doi:10.3109/02770900903483816 · Cited by 45
Emerging drugs for atopic dermatitis
Ong, P. Y. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902721248 · Cited by 34
Regulation of Interleukin-13 Receptor Constituents on Mature Human B Lymphocytes
Ogata, H., Ford, D., KOUTTAB, N. M., King, T. C., Vita, N., Minty, A. J., Stoeckler, J. D., Morgan, D., Girasole, C., Morgan, J. W., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.16.9864 · Cited by 34
Omalizumab for the treatment of chronic urticaria
Zuberbier, T., & Maurer, M. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.993971 · Cited by 30
State of the Art Treatment of Nasal Polyposis
Aouad, R. K., & Chiu, A. G. (2011) · American Journal of Rhinology and Allergy · doi:10.2500/ajra.2011.25.3681 · Cited by 29
17q21 gene variation is not associated with asthma in adulthood
Kreiner‐Møller, E., Strachan, D. P., Linneberg, A. R., Husemoen, L. L. N., Bisgaard, H. F., & Bønnelykke, K. (2014) · Allergy · doi:10.1111/all.12537 · Cited by 24
U.S. Food and Drug Administration: Juice HACCP — The Final Rule
Kautter, D. (2003) · CRC Press eBooks · doi:10.1201/9780203491201.ch6 · Cited by 24
Wagner, F. M., Fischer, N., Lersch, C., Hart, R., & Dancygier, H. (1989) · Immunology Letters · doi:10.1016/0165-2478(89)90110-7 · Cited by 19
At the bedside: the emergence of group 2 innate lymphoid cells in human disease
Peebles, R. S. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3bt0814-383r · Cited by 17
Advances in Management of Atopic Dermatitis: New Therapies and Novel Uses of Existing Treatments
Chase, E. P., & Armstrong, A. W. (2012) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2011.11.005 · Cited by 16
Berger, W. E., Kerwin, E., Bernstein, D. I., Pedinoff, A. J., Bensch, G. W., & Karafilidis, J. (2009) · Allergy and Asthma Proceedings · doi:10.2500/aap.2009.30.3242 · Cited by 15
Bronchoprovocation Testing in Asthma
Covar, R. A. (2007) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2007.09.005 · Cited by 15
Allergy, Asthma, and Inflammation: Which Inflammatory Cell Type Is More Important?
Moqbel, R., & Odemuyiwa, S. O. (2008) · Allergy Asthma and Clinical Immunology · doi:10.1186/1710-1492-4-4-150 · Cited by 14
Bronchoprovocation Testing in Asthma
Katial, R. K., & Covar, R. A. (2012) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2012.06.002 · Cited by 14
Methods used in clinical development of novel anti-asthma therapies
Diamant, Z., Boot, J. D., Kamerling, I. M. C., & Bjermer, L. H. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2007.10.018 · Cited by 12
Radin, A. R., Ren, H., Papino-Wood, P., Chaudhry, U. A., & Hamilton, J. D. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.12.1224 · Cited by 11
Inhibition of IL-4 and IL-13 with an IL-4 mutein (Aeroderm) protects against flares in atopic eczema
Groves, R. W., Wilbraham, D., Fuller, R. W., & Longphre, M. V. (2007) · Research Portal (King's College London) · Cited by 9
Dupilumab in chronic sinusitis with nasal polyposis, with and without asthma
Bachert, C., Mannent, L., Naclerio, R., Mullol, J., Ferguson, B., Jiao, L., Wang, L., Evans, R., Pirozzi, G., Graham, N., et al. (2015) · Ghent University Academic Bibliography (Ghent University) · Cited by 8
Self-citation
Research works printed but not linked: 5
- Pawankar, R., Canonica, G., Holgate, S. & Lockey, R. WAO White Book on Allergy 2011–2012: Executive Summary (World Allergy Organization, 2011).
- Wenzel, S. E. et al. Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma. Eur. Respir. J. 36 (Suppl. 54), 713s (2010).
- Wenzel, S. et al. Dupilumab improves lung function and reduces severe exacerbations in uncontrolled asthmatics with baseline eosinophil levels above and below 300 cells/μl. Am. J. Respir. Crit. Care Med. 191, A3632 (2015).
- Kaiser, J. Medical Officer's Efficacy Review, Genentech, Omalizumab BLA STN 103976/0. US Food and Drug Administration [online] , (2003).
- Groves, R., Wilbrahams, D., Fuller, R. & Longphre, M. Inhibition of IL-4 and IL-13 with an IL-4 mutein (Aeroderm) protects against flares in atopic eczema. J. Invest. Dermatol. 127 (Suppl. 1s), S54 (2007).
Cited by
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationLangan, S. M., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,852
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Blauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Self-citationWenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citation
Metadata
- Authors
- Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D.
- Affiliations
- Regeneron (United States) (US)
- Sanofi (United States) (US)
- Corresponding author
- Gandhi, Namita A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-10-16
- Volume
- 15
- Issue
- 1
- Pages
- 35-50
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2200308911
- Cited by
- 766
- References
- 156
- Citations by year
- 2026: 70 · 2025: 104 · 2024: 113 · 2023: 77 · 2022: 106 · 2021: 99 · 2020: 63 · 2019: 43 · 2018: 33 · 2017: 38 · 2016: 18
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Keywords
- type 2 inflammation, IL-4, IL-5, IL-13, asthma, atopic dermatitis, Th2 cells, allergic diseases, IL-4 receptor alpha inhibition, IL-13 inhibition, IL-5 inhibition, personalized asthma therapy, drug candidates
- MeSH terms
- Antibodies, Monoclonal, T-Lymphocytes, Helper-Inducer, Humans, Inflammation, Interleukin-4, Interleukin-5, Models, Immunological, Interleukin-13, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.